Home link About Biomediq

About Biomediq

Biomediq is a research-based company providing software-based solutions for clinical trials and clinical practice

    We perform contract research and market validated, automatic and semi-automatic analyses of:
  • knee MRI for scoring of cartilage quantity (volume, thickness, ...) and quality (surface smoothness, homogeneity, congruity, ...); and bone structure in relation to osteoarthritis
  • mammograms for breast cancer risk
  • atrophy and tissue structure from Brain MRI for Alzheimer's disease
  • synovitis and erosions from Hand MRI for rheumatoid arthritis


Biomediq A/S is a spin out of the CCBR-Synarc/Nordic Bioscience family of companies. On the basis of long term collaboration between the Image Groups at the Department of Computer Science, University of Copenhagen (DIKU) and the IT University of Copenhagen, the company was originally established as a research department of Nordic Bioscience in January 2007. In 2008 it was made into a daughter company, first named Nordic Bioscience Imaging, and then renamed Synarc Imaging Technologies. In spring 2011, Biomediq A/S was bought by management to form an independent company, to expand the customer basis outside the family and to broaden the business strategy to enter new markets.

Biomediq remains in close collaboration with the Image Group at DIKU in co-sponsored research projects. Prof. Mads Nielsen is founding CEO of Biomediq and Head of the Image Group.


The strategy of biomediq is to research, develop and implement quantitative imaging biomarkers for use in clinical trials and patient diagnosis, prognosis, screening, and monitoring.

The services of Biomediq help sponsors from Pharma and Clinical Research Organizations improving their trial design and insight gained from trials by using novel imaging markers. Automated analysis of scans provide quantitative markers. New markers are developed by machine learning technologies based on large databases of patient information. Markers are validated in clinical studies. Major therapeutic areas are osteoarthritis, rheumatoid arthritis, breast cancer, and Alzheimer's disease.


Major collaborators are Nordic Bioscience, CCBR-Synarc, Novartis, Erasmus Medical Center (Rotterdam University), University of California (SF), Mayo Clinic, ...